StockDuty ← Dashboard Oct 26, 2026 03:44 PM ET
SignalCorporate

Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?

Biogen Q3 preview questions whether growth products will drive an earnings beat.

What happened: Zacks expects Biogen $BIIB to beat expectations when it reports third-quarter 2026 results on Oct. 28, before market open, citing growth products offsetting lower multiple sclerosis drug sales. Key numbers: Consensus Q3 sales $2.60 billion and earnings $2.05 per share. Why it matters: The model predicts an earnings beat on the combination of a positive Earnings ESP and Zacks Rank #3. Growth products exceeded legacy MS portfolio revenue in the second quarter and are expected to keep the lead in the second half of 2026. Market: -0.1% today ($250.31), +40.8% YTD, 0.1x vol — as of 15:32 UTC Verified: Q3_2026 (Oct 28) revenue $2.6B vs $2.6B est; next print ~Jan 27
Zacks expects Biogen $BIIB to beat expectations when it reports third-quarter 2026 results on Oct. 28, before market open, citing growth products offsetting lower multiple sclerosis drug sales.
The model predicts an earnings beat on the combination of a positive Earnings ESP and Zacks Rank #3. Growth products exceeded legacy MS portfolio revenue in the second quarter and are expected to keep the lead in the second half of 2026. Market: -0.1% today ($250.31), +40.8% YTD, 0.1x vol — as of 15:32 UTC Verified: Q3_2026 (Oct 28) revenue $2.6B vs $2.6B est; next print ~Jan 27
Sources